Alnylam Pharmaceuticals (NASDAQ:ALNY) and Immuneering (NASDAQ:IMRX) Financial Review

Immuneering (NASDAQ:IMRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Immuneering and Alnylam Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1	0	5	1	2.86
Alnylam Pharmaceuticals	0	6	20	1	2.81

Immuneering presently has a consensus target price of $16.50, suggesting a potential upside of 210.15%. Alnylam Pharmaceuticals has a consensus target price of $468.84, suggesting a potential upside of 42.63%. Given Immuneering’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immuneering is more favorable than Alnylam Pharmaceuticals.

Earnings and Valuation

This table compares Immuneering and Alnylam Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03 million	($1.38)	-3.86
Alnylam Pharmaceuticals	$3.71 billion	11.74	$313.75 million	$1.71	192.22

Alnylam Pharmaceuticals has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Immuneering has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Profitability

This table compares Immuneering and Alnylam Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-43.33%	-39.75%
Alnylam Pharmaceuticals	6.43%	69.02%	5.15%

Summary

Alnylam Pharmaceuticals beats Immuneering on 9 of the 13 factors compared between the two stocks.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.